An evaluation of the FDA adverse event reporting system and the potential for reporting bias

被引:5
|
作者
Monnot, Andrew D. [1 ]
Fung, Ernest S. [2 ]
Compoginis, Goli S. [3 ]
Towle, Kevin M. [1 ]
机构
[1] Cardno ChemRisk, 235 Pine St,Suite 2300, San Francisco, CA 94104 USA
[2] Cardno ChemRisk, Aliso Viejo, CA USA
[3] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
关键词
adverse event reporting; cosmetics; news media;
D O I
10.1111/jocd.14065
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The FDA maintains the Adverse Event Reporting System (CAERS) database, which contains product complaint reports for foods, dietary supplements, and cosmetics. Product line perception and subsequent adverse event reporting may be impacted by negative media attention. Methods The purpose of this analysis was to use the CAERS database to analyze temporal trends in adverse event reporting before and after media coverage of alleged health effects, using WEN by Chaz Dean (WCD) cleansing conditioners as a case study. WCD cleansing conditioner adverse event reports from January 2005 to December 2018 were abstracted from the CAERS database. Zero-inflated negative binomial regression models were used to analyze the rate of adverse events (WCD events/10,000 WCD cleansing conditioner units sold/month), adjusted for temporal trends in CAERS. Results There was a statistically significant higher rate of adverse event reporting after negative media coverage in December 2015 (IRR 16.71 [95% CI: 7.89-35.39]) when compared to the rate of adverse event reporting before December 2015. Conclusions This analysis highlights the importance of assessing potential external factors, such as negative news media coverage, that may alter reporting behaviors due to societal shifts in product-specific risk perception. Consideration of these factors in post-market surveillance programs would result in more comprehensive safety evaluations.
引用
收藏
页码:1849 / 1854
页数:6
相关论文
共 50 条
  • [1] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [2] Identification of Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha S.
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 406 - 407
  • [3] An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the FDA combined spontaneous reporting system/adverse event reporting system
    Schnell, FM
    Coop, AJ
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (05): : 409 - 419
  • [4] REPORTING FREQUENCY OF QT-INTERVAL ABNORMALITIES IN THE FDA ADVERSE EVENT REPORTING SYSTEM (FDA_AERS)
    Raschi, E.
    Poluzzi, E.
    Koci, A.
    De Ponti, F.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 84 - 84
  • [5] An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System
    Kathryn Marwitz
    S. Christopher Jones
    Cindy M. Kortepeter
    Gerald J. Dal Pan
    Monica A. Muñoz
    [J]. Drug Safety, 2020, 43 : 457 - 465
  • [6] An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System
    Marwitz, Kathryn
    Jones, S. Christopher
    Kortepeter, Cindy M.
    Dal Pan, Gerald J.
    Munoz, Monica A.
    [J]. DRUG SAFETY, 2020, 43 (05) : 457 - 465
  • [7] IN VIDEO, FDA URGES ADVERSE EVENT REPORTING
    Cima, Greg
    [J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2021, 259 (03): : 223 - 223
  • [8] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
    Pankdeep Chhabra
    Xing Chen
    Sheila R. Weiss
    [J]. Drug Safety, 2013, 36 : 1117 - 1123
  • [9] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
    Chhabra, Pankdeep
    Chen, Xing
    Weiss, Sheila R.
    [J]. DRUG SAFETY, 2013, 36 (11) : 1117 - 1123
  • [10] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
    Altman, Keith
    Budny, Renata
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400